A part of Watch Media

MedWatchThursday5 October 2023

  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
MedWatchThursday5 October 2023
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
Pharma & biotech

Zevra to finish what Orphazyme started: "We have set ourselves up for success"

Zevra Therapeutics, which bought Orphazyme’s failed rare disease candidate last year, has what the embattled developer needed: time and money.
by mikkel aabenhus hemmingsen, translated by daniel pedersen

Orphazyme’s former drug candidate arimoclomol had already been rejected by the US Food and Drug Administration (FDA) – and was likely about to be rejected by the European Medicines Agency (EMA) as well, before the developer retracted its marketing application. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Related articles:

  • Name change to connect Orphazyme buyer Kempharm with rare disease area

    For subscribers

  • Anders Hinsby (left), Thomas Kirkegaard Jensen, and Anders Vadsholt | Photo: Anne Bæk/Ritzau Scanpix

    Orphazyme trio founds new firm focused on neurology and rare diseases

    For subscribers

  • Photo: Andrew Kelly/Reuters/Ritzau Scanpix

    Orphazyme buyer intends to resubmit failed drug candidate for FDA approval

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Photo: Staff/Reuters/Ritzau Scanpix
Pharma & biotech

Novo Nordisk suffers Wegovy defeat to Viatris in patent court

It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.
  • Novo Nordisk's semaglutide to be studied for positive effect on alcoholics
  • FDA approves Novo Nordisk drug to treat rare condition


Foto: Mike Blake
Pharma & biotech

Eli Lilly's head of diabetes and obesity retires

For subscribers



Pharma & biotech

DNB expects ALK's tablet sales to recover in 2024

For subscribers


Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Photo: Pr
Pharma & biotech

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

For subscribers


Foto: Novo Nordisk / Pr
Pharma & biotech

Pharmaceutical industry to grow 4% annually towards 2030

For subscribers


Photo: Stine Bidstrup
Pharma & biotech

Zealand Pharma CEO: "We've never been stronger"

For subscribers


  • Foto: Tom Little

    Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom

    The market’s attention is more focused on public health insurance Medicare’s new price negotiations under the so-called Inflation Reduction Act.

    For subscribers


  • Foto: Tom Little

    FDA approves Novo Nordisk drug to treat rare condition

    The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

    For subscribers


  • Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr

    Fujifilm expands management with former Leo executive

    The contract manufacturer has hired a chief people officer with immediate effect.

    For subscribers


  • Foto: Andrew Kelly/Reuters/Ritzau Scanpix

    Low share price may knock Galecto off the stock exchange

    Nasdaq has requested that the biotech company raise its share price to above USD 1.

    For subscribers


  • Foto: Mike Segar/Reuters/Ritzau Scanpix

    Snack maker keeps an eye on Novo Nordisk's obesity drug

    ”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.

  • Foto: Yuriko Nakao/Reuters/Ritzau Scanpix

    Olympus appoints new chief medical officer

    The new medical director is brought in from Medtronic. 

    For subscribers


Further reading

Foto: Mike Segar
Pharma & biotech

FDA rejects atopic dermatitis drug lebrikizumab

Eli Lilly had expected a launch this year.

For subscribers



Photo: Staff/Reuters/Ritzau Scanpix
Pharma & biotech

Novo Nordisk suffers Wegovy defeat to Viatris in patent court

It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.


Foto: Mike Blake
Pharma & biotech

Eli Lilly's head of diabetes and obesity retires

Mike Mason announces that he will retire at the end of the year after 34 years with the company.

For subscribers


Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Photo: Pr
Pharma & biotech

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

The amount of cash that Eli Lilly had to fork out to gain dominion of Immunitrack has been kept under wraps.

For subscribers



Novo Nordisk's manufacturing facility in Clayton, the US. | Foto: Novo Nordisk/pr
Pharma & biotech

Novo Nordisk facility in the US allegedly receives FDA notice

The FDA has reportedly notified the company’s management of problematic conditions.

For subscribers



EMA’s rådgivende panel, CHMP, anbefaler at godkende lægemiddelkandidaten Transcon PTH, som det dansk-amerikanske biotekfirma Ascendis Pharma står bag. | Foto: Kevin Grønnemann / Medwatch
Pharma & biotech

EMA committee recommends drug candidate from Ascendis Pharma

In the US, the FDA rejected the drug candidate TransCon PTH in May, but in Europe, the path now seems clear for the Danish-American biotech company’s hypoparathyroidism drug to be approved.

For subscribers


Jobs

  • Global Medical Manager

  • Senior CMC Specialist, Upstream Processing, Genmab

  • VP of Software Development, Perfusion Tech

  • Audit & Supplier Manager

  • Project Director, HR & ESG

  • Qualified Person to AJ Vaccines

  • Chemist for Incoming Materials in QC department

  • Discovery Project Leader, Principal Scientist

  • QA/RA Manager

  • Scientist - Bioanalysis, Biologics

  • Clinical Trial Manager

  • Senior Legal Councel

  • Clinical Supply Manager

  • Senior QA Specialists (GMP or GCP)

  • Director, Head of Antibody Technology

See all jobs

Latest news

  • Novo Nordisk suffers Wegovy defeat to Viatris in patent court –
  • Pharmaceutical industry to grow 4% annually towards 2030 –
  • Zealand Pharma CEO: "We've never been stronger" –
  • Eli Lilly's head of diabetes and obesity retires –
  • DNB expects ALK's tablet sales to recover in 2024 –
  • Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees –
  • Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom –
  • Novo Nordisk's semaglutide to be studied for positive effect on alcoholics –
  • Olympus appoints new chief medical officer –
  • Low share price may knock Galecto off the stock exchange –
See all

Jobs

  • Global Medical Manager

  • Senior CMC Specialist, Upstream Processing, Genmab

  • VP of Software Development, Perfusion Tech

  • Audit & Supplier Manager

  • Project Director, HR & ESG

  • Qualified Person to AJ Vaccines

  • Chemist for Incoming Materials in QC department

  • Discovery Project Leader, Principal Scientist

  • QA/RA Manager

  • Scientist - Bioanalysis, Biologics

  • Clinical Trial Manager

  • Senior Legal Councel

  • Clinical Supply Manager

  • Senior QA Specialists (GMP or GCP)

  • Director, Head of Antibody Technology

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

  • About MedWatch

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Banner Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved